Author

Rocio Manghani

Observed name: Manghani, Rocio

ORCID: 0000-0001-5564-3618

Observed ORCID: 0000-0001-5564-3618

OpenAlex ID: A5018575645

Health care costs among patients with hematologic malignancies receiving allogeneic transplants: a US payer perspective

2023 · Richard T. Maziarz, Usama Gergis, et al. · Blood Advances · 15

Health-Related Quality of Life Following Allogeneic Hematopoietic Cell Transplantation with Omidubicel versus Umbilical Cord Blood

2022 · Chenyu Lin, Gautam Sajeev, et al. · Transplantation and Cellular Therapy · 12

Hospitalization and Healthcare Resource Utilization of Omidubicel-Onlv versus Umbilical Cord Blood Transplantation for Hematologic Malignancies: Secondary Analysis from a Pivotal Phase 3 Clinical Trial

2023 · Navneet S. Majhail, Beckley Miller, et al. · Transplantation and Cellular Therapy · 3

Hospitalization and Healthcare Resource Use of Omidubicel Vs Cord Blood Transplantation for Hematological Malignancies in a Global Randomized Phase III Clinical Trial

2021 · Navneet S. Majhail, Beckley Miller, et al. · Blood · 3

Projected Impact of Omidubicel-onlv on Racial/Ethnic Disparities in Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Outcomes in Hematologic Malignancies

2024 · Nandita Khera, Marie Louise Edwards, et al. · Advances in Therapy · 2

Clinical Outcomes Following Allogeneic Hematopoietic Cell Transplantation with Omidubicel or Other Donor Sources in Patients with Hematologic Malignancies: Comparison of Clinical Trial Results to Center for International Blood and Marrow Transplant Research Database Controls

2022 · Smitha Sivaraman, Gautam Sajeev, et al. · Blood · 2

Abstract 6 Projected Impact of Omidubicel on Racial and Ethnic Disparities in Allogeneic Hematopoietic Cell Transplant Access and Outcomes for Patients with Hematologic Malignancies in the U.S.

2022 · Usama Gergis, Nandita Khera, et al. · Stem Cells Translational Medicine · 2

CT-039 Health-Related Quality of Life Following Allogeneic Hematopoietic Stem Cell Transplantation With Omidubicel Versus Standard Umbilical Cord Blood

2022 · Chenyu Lin, Gautam Sajeev, et al. · Clinical Lymphoma Myeloma & Leukemia · 1

Hospitalization and Healthcare Resource Use of Omidubicel Vs Umbilical Cord Blood (UCB) for Hematological Malignancies in a Global Randomized Phase III Clinical Trial Setting

2022 · Navneet S. Majhail, Beckley Miller, et al. · Transplantation and Cellular Therapy · 1

Orca-T Demonstrates Favorable Quality of Life and Healthcare Resource Use Compared to Standard Allohsct Plus Tac/MTX for GVHD Prevention in a Randomized phase 3 Clinical Trial (Precision-T)

2026 · Arpita Gandhi, Anna Pavlova, et al. · Transplantation and Cellular Therapy

Cost-Effectiveness of Orca-T Vs Allo-HCT with Conventional GVHD Prophylaxis for the Treatment of Advanced Hematologic Malignancies in the United States

2026 · Rawan Faramand, James Scott McClellan, et al. · Transplantation and Cellular Therapy

Correction to: Projected Impact of Omidubicel-onlv on Racial/Ethnic Disparities in Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Outcomes in Hematologic Malignancies

2024 · Nandita Khera, Marie Louise Edwards, et al. · Advances in Therapy

Poster: CT-039 Health-Related Quality of Life Following Allogeneic Hematopoietic Stem Cell Transplantation With Omidubicel Versus Standard Umbilical Cord Blood

2022 · Chenyu Lin, Gautam Sajeev, et al. · Clinical Lymphoma Myeloma & Leukemia

Abstract 8 Health-Related Quality of Life (HRQL) Following Transplantation with Omidubicel Versus Umbilical Cord Blood (UCB) in Patients with Hematologic Malignancies: Results from a Phase III Randomized, Multicenter Study

2022 · Chenyu Lin, Gautam Sajeev, et al. · Stem Cells Translational Medicine

Total Costs of Care and Complication Rates Among Patients with Hematologic Malignancies Who Receive Allogeneic Hematopoietic Cell Transplants in the US

2022 · Richard T Maziarz, Marie Louise Edwards, et al. · Transplantation and Cellular Therapy

Health-Related Quality of Life (HRQL) Following Transplantation with Omidubicel Versus Umbilical Cord Blood (UCB) in Patients with Hematologic Malignancies: Results from a Phase III Randomized, Multicenter Study

2022 · Mitchell E. Horwitz, Gautam Sajeev, et al. · Transplantation and Cellular Therapy

Projected Impact of Omidubicel on Racial and Ethnic Disparities in Allogeneic Hematopoietic Cell Transplant Access and Outcomes for Patients with Hematologic Malignancies in the US

2022 · Usama Gergis, Nandita Khera, et al. · Transplantation and Cellular Therapy

Works count: 18

Citation count: 41

H-index: 3

I10-index: 2